InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,225.77
(
0.08%
)
US TECH 100
17,747.00
(
0.13%
)
Dow Jones
39,509.80
(
0.20%
)
Brent Oil
82.83
(
-0.46%
)
Bitcoin
61,514.46
(
-2.21%
)
Post# of 251817
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119628
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 209525

Wednesday, 03/29/2017 3:13:08 PM

Wednesday, March 29, 2017 3:13:08 PM

Post# of 251817
MYL -3% on CRL for generic Advair:

http://finance.yahoo.com/news/mylan-comments-generic-advair-diskus-171600156.html

In conjunction with Mylan's GDUFA goal date, the company received a complete response letter from FDA regarding its ANDA for generic Advair Diskus®. Mylan is in the process of reviewing this response and will provide an update on its application as soon as practicable once it has completed its review and discussed the FDA's feedback with the agency.

Due to the difficulty in replicating GSK's inhalation device, there is not yet any FDA-approved generic for Advair, but TEVA has submitted a 505b2 NDA for a (non-substitutable) Advair knockoff.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up